Quick Answer
BioNexus Gene Lab Corp reported Diluted EPS of $0.09 per share (loss) for fiscal year 2024.
BioNexus Gene Lab Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.09 | +45.8% |
| 2023 | -$0.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.40 | +47.3% | -15.2% |
| June 30, 2025 | -$0.34 | -403.5% | -880.0% |
| March 31, 2025 | -$0.04 | -483.3% | +95.3% |
| September 30, 2024 | -$0.75 | — | -762.8% |
| June 30, 2024 | $0.11 | — | +1983.3% |
| March 31, 2024 | -$0.01 | — | — |
- BioNexus Gene Lab Corp showed an increase of +45.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2024 period, BioNexus Gene Lab Corp’s diluted eps has grown by 45.8% (from $0.17 per share (loss) to $0.09 per share (loss)).
- The most recent figure is from BioNexus Gene Lab Corp’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: